Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 5

For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 21, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 5

For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 1

Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?

Recorded April 21, 2020.

COVID-19

William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic

William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and reviews best practices for treatment decisions, social distancing, and maintaining emotional health. Recorded April 15, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 5

For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement